It is not objectively good news, but Rocket Lab found a defect before risking catastrophic failure on the launchpad.

Rocket Lab's valuation is heavily dependent on unproven future projects, increasing risk for current shareholders. Read why ...

Rocket Lab heads into its third-quarter report with a striking disconnect. The business keeps setting records, the backlog keeps climbing, and management sounded more expansive last quarter than at ...

Rocket Lab’s reported decline from $151 in May to $54.73 on October 30 raises questions about the valuation of its expanding ...

Rocket Lab is keeping us waiting for Neutron.

Could two numbers in the space company's next report make its 61% drop a buying opportunity?

Rocket Lab Corporation remains a buy despite an expected nearly one-year Neutron rocket delay and increased perceived risk.

Management's schedule for positive adjusted EBITDA hinges on that first launch. Has the sell-off priced in the wait?

Rocket Lab's Neutron rocket just slipped past a key deadline, and Wall Street is starting to reprice how long investors will wait for the launch revenue that underpins the entire bull case.

Rocket Lab disclosed another major delay to its Neutron medium lift rocket after finding manufacturing and structural issues in key tanks, pushing the first launch to 2027 and requiring a redesign of ...

Rocket Lab stock (NASDAQ: RKLB) plunged as much as 13% in early Thursday trading after the company pushed the inaugural flight of its Neutron rocket into ...